Colorectal adenocarcinoma incidence is decreasing overall but increasing among individuals aged 15 to 34 years, with an APC of 1.75. Pancreatic adenocarcinoma incidence is rising across all age ...

In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent ...